Congress: The House of Representatives Foreign Affairs released a 90-Day Review Report of BIS.

Congress: The House of Representatives Foreign Affairs released a 90-Day Review Report of BIS.

Chairman McCaul determined that BIS has enabled a virtually unrestricted flow of American technology to CCP-controlled companies, facilitating China’s rapid rise as a technological, economic, and military superpower.
Read More

Related Posts

DoD: Evolving Priorities in Defense Contracting

The defense contracting landscape is undergoing a fundamental reset. Federal agencies are signaling a shift away from propping up contractors through guaranteed funding and extended timelines. Instead, firms are being pushed to invest their own capital, compete on merit, and deliver capabilities at wartime speed. Agility, innovation, and rapid execution are becoming decisive factors, while…

NMFS: Upcoming Import Prohibitions and Industry Webinars

The National Marine Fisheries Service (NMFS) announces that, effective January 1, 2026, imports of specific fish and fish products from countries whose fisheries have not received comparability findings under the Marine Mammal Protection Act (MMPA) will be restricted from entering the United States. To help industry prepare for these changes, NMFS will host two informational…

CBP: Settlement Reached in Aluminum Extrusions Duty Evasion Case

Harman International Industries, parent company of Harman Kardon®, JBL®, and Mark Levinson®-has agreed to pay $11,809,628 to settle allegations that it evaded antidumping and countervailing duties (ADCVD) on aluminum-extrusion heatsinks imported from China. According to the allegations, the company failed for more than a decade to disclose or correct the violations and actively concealed the…

USTR: U.S. and U.K. Reach Agreement on Pharmaceuticals and Medical Technology

On December 1, 2025, the United States and United Kingdom announced a new agreement on pharmaceuticals, pharmaceutical ingredients, and medical technology. Under this arrangement, the U.S. would remove Section 232 tariffs on U.K.-sourced medical goods, pause any Section 301 investigations related to U.K. pharmaceutical pricing during President Trump’s term, and collaborate to expand U.K. patient…